This page shows the latest Probuphine news and features for those working in and with pharma, biotech and healthcare.
Titan and Braeburn's Probuphine is first implant of its kind to win US approval. ... It found that 63% of patients treated with the Probuphine implant had no evidence of illicit opioid use throughout the six months of treatment.
In trials, Probuphine was shown to be non-inferior to daily treatment with oral buprenorphine, which is a partial opioid receptor agonist. ... At the committee meeting, Braeburn presented summary safety findings with a particular focus on the Probuphine
More from news
Approximately 2 fully matching, plus 0 partially matching documents found.
DeVarney joined Titan over ten years ago, and has lead the development of its opioid addiction treatment Probuphine.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.